{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Teglarinad_Chloride",
  "nciThesaurus": {
    "casRegistry": "432037-57-5",
    "chebiId": "",
    "chemicalFormula": "C30H43ClN5O8.Cl",
    "definition": "A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.",
    "fdaUniiCode": "D6V5QYX9MZ",
    "identifier": "C68931",
    "preferredName": "Teglarinad Chloride",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825"
    ],
    "synonyms": [
      "CHS828 Prodrug",
      "EB1627",
      "GMX1777",
      "Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino) methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-, chloride",
      "TEGLARINAD CHLORIDE",
      "Teglarinad Chloride"
    ]
  }
}